A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis
BMC Gastroenterology, ISSN: 1471-230X, Vol: 16, Issue: 1, Page: 8764-null
2016
- 10Citations
- 14Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes10
- 10
- CrossRef1
- Captures14
- Readers14
- 14
Article Description
Background: The incidence of the para-aortic lymph node metastasis (PALM) in patients with advanced gastric cancer is 6 to 33%. The prognosis is poor and the 5-year survival rate is only 12 to 23% after gastrectomy with super-extended lymph node dissection. We applied an individualized comprehensive treatment for affected patients including neoadjuvant chemotherapy via intra-arterial and intravenous administration, surgery and radiotherapy, to investigate the safety and prognostic value. Methods: Between January 2005 and December 2010, 47 advanced gastric cancer patients with PALM received 5-Fu (370mg/m) and leucovorin (200mg/m) intravenously on days 1-5, and intra-arterial infusion of etoposide (80mg/m) and oxaliplatin (80mg/m) on days 6 and 20, repeated 2cycles. Patients achieved PR or CR of the para-aortic lymph node (PAL) were performed D2 dissection, followed by 6cycles chemotherapy with XELOX regimen, oxaliplatin (130mg/m) on day 1 and xeloda (1000mg/m) on days 1 to 14 of a 28-day cycle, and radiotherapy to the region of PALM. Results: Forty-six patients completed 2cycles of neoadjuvant chemotherapy. The overall response rate of the primary tumor was 80.4% (37/46). The response rate of PAL was 76.1% (35/46). Thirty-two patients underwent D2 dissection and six cases achieved pathological complete response (pCR). The toxicity profile was well tolerable and there was no treatment-related death. The median survival time for all patients was 23months, and for nonsurgical and surgical patients were 12 and 29months (p<0.001), respectively. The 1-year, 2-year and 3-year survival rate was 70.96, 43.27 and 35.48% for all patients, and for surgical patients was 96.875, 68.75, and 40.63%. Conclusion: Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy, subsequent surgery and radiotherapy. Trial registration: Current Controlled Trials ChiCTR-TRC-12002046.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84955148652&origin=inward; http://dx.doi.org/10.1186/s12876-016-0422-7; http://www.ncbi.nlm.nih.gov/pubmed/26782354; http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0422-7; https://dx.doi.org/10.1186/s12876-016-0422-7; https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0422-7; https://bmcgastroenterol.biomedcentral.com/counter/pdf/10.1186/s12876-016-0422-7; http://www.biomedcentral.com/1471-230X/16/8; http://link.springer.com/article/10.1186/s12876-016-0422-7/fulltext.html; https://link.springer.com/article/10.1186/s12876-016-0422-7; https://link.springer.com/content/pdf/10.1186%2Fs12876-016-0422-7.pdf
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know